Tulane National Primate Research Center

本申请申请为杜兰国家灵长类动物研究中心(TNPRC)提供五年的资金 从2008年5月1日至2013年4月30日。资金将用于支持政府， 业务、兽医资源、科研资源和教育培训任务 中心。支持试点研究项目和与群体健康相关的研究资源的额外资金 项目也被要求。 近三十年来，TNPRC研究项目的主要重点一直是传染病。 这种情况将继续下去。此外，与美国疾病控制与预防中心密切相关的一个重要的基因治疗项目 杜兰大学的基因疗法在过去五年里得到了发展。该计划的主要资助范围 传染病方案目前有艾滋病、莱姆病和生物防御相关的制剂；还有 发展中的领域，如结核病。这些是涉及调查人员的多学科研究 TNPRC的多个部门和中心外的合作者。这些研究涵盖了以下方面的光谱 传播和发病机制到疫苗策略和化疗治疗的发展。这个 基因治疗计划提供了与大学其他部门的重要联系，允许采用新的方法来 治疗多种类型的疾病，并为我们的研究计划带来额外的多样性。 自上次提交TNPRC基本赠款以来，这段时间是一个显著增长的时期， 中心的进步。赞助资金总额大幅增加，个人、研究人员 发起的奖励现在超过了上次提交基本赠款时的总奖励。我们目前在 开始对我们的设施进行重大扩展，以支持不断增长的研究计划。总数 目前项目的建设预算超过5000万美元，将使 设施。扩建的资金来自许多NIH建设奖项(C06，UC6)和私人资金。的 特别要注意的是区域生物安全实验室。这是一个BSL-3设施，将专注于生物防御和 新出现的感染，以支持NIH生物防御研究议程。 根据过去五年的进展，我们对未来非常乐观。其优势所在 我们可以利用包括重大资助的改建和扩建项目在内的研究重点(传染性 疾病和基因治疗)与NIH和国家优先事项相匹配，教师任命，强大和 多样化的研究资源，有才华和敬业精神的员工，与 地区大学和与我们的主办机构以及州和联邦立法者的良好关系。

This application requests funding for the Tulane National Primate Research Center (TNPRC) for the fiveyear period beginning May 1, 2008 through April 30, 2013. Funds will be used to support the administration, operations, veterinary resources, scientific research resources and education and training mission of the Center. Additional funds to support pilot research projects and colony-health-related research resource projects are also requested. For nearly three decades the main focus of the TNPRC research program has been infectious disease. This will continue. In addition, a significant program in gene therapy that is tightly linked to the Center for Gene Therapy at Tulane has developed over the last five years. The major areas of funding for the infectious disease program are currently AIDS, Lyme disease and biodefense-related agents; there are also areas under development, such as tuberculosis. These are multidisciplinary studies involving investigators in multiple Divisions at the TNPRC and collaborators outside the Center. The studies cover the spectrum from transmission and pathogenesis to development of vaccine strategies and chemotherapeutic treatments. The gene therapy program provides an important link to the rest of the University, allows for novel approaches to the treatment of many types of disease and imparts additional diversity to our research program. The period since the last submission of the TNPRC base grant has been a time of significant growth and improvement at the Center. Total sponsored funding has increased dramatically and individual, investigator initiated awards now exceed total awards at the time of the last base grant submission. We are currently at the beginning of a major expansion of our facilities in support of the growing research program. The total construction budget for current projects is in excess of $50M and will add approximately 80,000sf to the facility. The expansion is funded by numerous NIH construction awards (C06, UC6) and private funds. Of particular note is the Regional Biosafety Laboratory. This is a BSL-3 facility that will focus on biodefense and emerging infections in support of the NIH biodefense research agenda. Based on the progress in the last five years we are very optimistic about the future. Strengths on which we can capitalize include significant funded renovation and expansion projects, a research focus (infectious diseases and gene therapy) that matches NIH and national priorities, faculty appointments, strong and diverse research resources, a talented and dedicated staff, excellent interactions and collaborations with area universities and an outstanding relationship with our host institution and state and federal legislators.